Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=award_id
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_id", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=award_id", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=award_id", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=award_id" }, "data": [ { "type": "Grant", "id": "15768", "attributes": { "award_id": "75N92023D00011-0-759202500001-1", "title": "COPD GENE - GENETIC EPIDEMIOLOGY OF COPD - TASK AREA A: YEAR 3 - AUGUST 10, 2025 - AUGUST 9, 2026", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2025-08-10", "end_date": "2026-08-09", "award_amount": 9292344, "principal_investigator": { "id": 32839, "first_name": "LEE S", "last_name": "NEWMAN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2636, "ror": "", "name": "NATIONAL JEWISH HEALTH", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "Genetic Epidemiology of COPD (COPDGene) is a multi-site longitudinal cohort study of current and former smokers to better understand risk factors, natural history, and genetic contributions of chronic obstructive pulmonary disease (COPD) as well as other smoking-related diseases. The purpose of this acquisition is to fund a 15-year follow-up in-person clinical visit (Visit 4) of this cohort, to be re-enrolled from approximately 19 active Clinical Study Centers. A Visit 4 of COPDGene subjects is needed to identify clinical, physiological, imaging, and Omics determinants of COPD and other disease progression in elderly subjects, to assess the impact of COVID-19 on COPD and other disease progression, and to discover determinants of severe COPD development in subjects with preserved ratio, impaired spirometry (PRISm). The acquisition will also support the maintenance of previously collected data and biospecimens, regulatory oversight of the study, and analysis of study data and study biospecimens. The goal of COPDGene is to use extensive longitudinal imaging, physiology, and Omics molecular data in combination with genetics in the COPDGene cohort to identify high-risk subgroups with distinct diagnostic, prognostic, and therapeutic implications. COPDGene has been funded for 15 years through grants and cooperative agreements awarded by NHLBI to National Jewish Health and Brigham and Women’s Hospital. Grant applications for the three Phases of COPDGene [Phase 1: baseline visit (“Visit 1”); Phase 2: five year follow-up (“Visit 2”); Phase 3: ten year follow-up (“Visit 3”)] were all submitted to the parent NIH R01 Funding Opportunity Announcement. Study investigators originally recruited 10,198 current or former smokers in Phase 1. Including nonsmoking controls from both Phase 1 and Phase 2, COPDGene has recruited a total 10,718 subjects all of whom have been extensively phenotyped clinically and radiologically. Additional data collected on these participants include whole genome sequencing as well as RNA sequencing, proteomics, metabolomics, and DNA methylation data from collected blood samples. Investigators have published more than 450 publications, the vast majority of which were peer-reviewed, using COPDGene data. COPDGene also serves as a parent study for many ancillary studies, using public or private funding, a subset of which have collected additional data on all or a subset of participants. COPDGene is overseen by an NHLBI-convened Observational Study Monitoring Board (OSMB). The Visit 4 (15-year follow-up) evaluations will include, where possible, lung function tests (spirometry), questionnaires (including COVID-19 assessment), chest computerized tomography (CT), other functional assessments (e.g., six minute walk distance), and collection and storage of biospecimens from 3,500 of the original 10,718 COPDGene subjects. In addition, this acquisition will support continuation of semi-annual long-term follow-up of the COPDGene cohort and other contact with the cohort as needed, oversight of clinical sites and human subjects protection, maintenance of the database and biobank, continued coordination with NIH and NHLBI data resources, activities relevant to the data management and sharing plan, analysis of data, travel to meetings, and publication costs.", "keywords": [ "Address", "Adverse event", "Ancillary Study", "Annual Reports", "Applications Grants", "Archives", "Area", "Award", "Bioinformatics", "Biological Markers", "Biological Specimen Banks", "Blood specimen", "Bronchodilator Agents", "COVID-19", "COVID-19 impact", "Cause of Death", "Certification", "Cessation of life", "Characteristics", "Chest", "Chronic Obstructive Pulmonary Disease", "Clinical", "Clinical Data", "Clinical Research", "Clinical/Radiologic", "Collaborations", "Collection", "Communication", "Communities", "Compensation", "Computer Security", "Contractor", "Contracts", "DNA Methylation", "Data", "Data Analyses", "Data Coordinating Center", "Data Science", "Data Security", "Data Set", "Databases", "Development", "Diagnostic", "Diffusion", "Disease Progression", "Documentation", "Educational workshop", "Elderly", "Electronics", "Enrollment", "Ensure", "Epidemiology", "Evaluation", "Event", "Funding", "Funding Opportunities", "Future", "Genes", "Genetic", "Genomics", "Goals", "Grant", "Health", "Hospitals", "Image", "Impairment", "Information Systems", "Institutional Review Boards", "International", "Internet", "Jews", "Journals", "Laboratories", "Link", "Long-term Follow-up", "Longitudinal cohort study", "Maintenance", "Manuscripts", "Measures", "Medical History", "Metadata", "Methods", "Molecular", "Monitor", "Names", "National Heart Lung and Blood Institute", "Natural History", "Observational Study", "Outcome", "Oxygen", "Parents", "Participant", "Peer Review", "Persons", "Phase", "Physical Performance", "Physiological", "Physiology", "Policies", "Privatization", "Procedures", "Proteomics", "Protocols documentation", "PubMed", "Publications", "Publishing", "Pulmonary Emphysema", "Pulmonary function tests", "Quality Control", "Quality of life", "Questionnaires", "Recommendation", "Reporting", "Research", "Research Personnel", "Resolution", "Resources", "Risk Factors", "SARS-CoV-2 infection", "Scanning", "Schedule", "Scientist", "Site", "Specific qualifier value", "Spirometry", "Standardization", "Subgroup", "Support Contracts", "System", "Teleconferences", "Telephone", "Testing", "Therapeutic", "Time", "Tobacco use", "Training", "Trans-Omics for Precision Medicine", "Travel", "U-Series Cooperative Agreements", "United States National Institutes of Health", "Update", "Vaccination", "Visit", "Walking", "Woman", "Work", "X-Ray Computed Tomography", "adjudication", "biobank", "catalyst", "clinical ce" ], "approved": true } }, { "type": "Grant", "id": "9058", "attributes": { "award_id": "75N93019C00015-P00001-9999-2", "title": "NIAID VIROLOGY QUALITY ASSURANCE (VQA) COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-06-21", "end_date": "2021-06-20", "award_amount": 668265, "principal_investigator": { "id": 24151, "first_name": "THOMAS", "last_name": "DENNY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "The purpose of the NIAID Virology Quality Assurance (VQA) program is to provide a comprehensive quality assessment program for virologic assays for HIV, and other viral pathogens, performed on samples from subjects enrolled in NIAID-sponsored multisite clinical studies. The VQA program ensures the validity and inter- and intra-laboratory comparability of virologic laboratory data obtained from NIAID-supported clinical trials and HIV natural history studies by providing laboratories with proficiency testing panels and real-time assay run controls and analyzing proficiency panel and assay run data from each laboratory. The VQA program also implements standards of performance for existing and state-of-the-art new virologic assays, develops and tests biostatistical methods relating to the assays, and acquires, tests, stores and dispenses quality control materials and reagents. Support under this project is for SARS-CoV-2 (COVID-19) virologic assay quality assurance activities.", "keywords": [ "2019-nCoV", "Biological Assay", "Biostatistical Methods", "Blood", "Blood specimen", "COVID-19", "Cells", "Clinical Trials", "Data", "Diagnosis", "Enrollment", "Ensure", "HIV", "Infection", "Inpatients", "Laboratories", "Methods", "Multi-site clinical study", "National Institute of Allergy and Infectious Disease", "Natural History", "Outpatients", "Patients", "Performance", "Plasma", "Quality Control", "Reagent", "Research", "Reverse Transcriptase Polymerase Chain Reaction", "Running", "Saliva", "Sampling", "Serum", "Site", "Swab", "Testing", "Time", "Tube", "Validation", "Viral", "Viral Load result", "Virus", "pathogenic virus", "programs", "quality assurance", "virology" ], "approved": true } }, { "type": "Grant", "id": "8366", "attributes": { "award_id": "75N93019C00015-P00004-9999-2", "title": "COVID-19: NIAID VIROLOGY QUALITY ASSURANCE (VQA)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-06-21", "end_date": "2022-06-20", "award_amount": 641460, "principal_investigator": { "id": 24151, "first_name": "THOMAS", "last_name": "DENNY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "The purpose of the NIAID Virology Quality Assurance (VQA) program is to provide a comprehensive quality assessment program for virologic assays for HIV, and other viral pathogens, performed on samples from subjects enrolled in NIAID-sponsored multisite clinical studies. The VQA program ensures the validity and inter- and intra-laboratory comparability of virologic laboratory data obtained from NIAID-supported clinical trials and HIV natural history studies by providing laboratories with proficiency testing panels and real-time assay run controls and analyzing proficiency panel and assay run data from each laboratory. The VQA program also implements standards of performance for existing and state-of-the-art new virologic assays, develops and tests biostatistical methods relating to the assays, and acquires, tests, stores and dispenses quality control materials and reagents. Support under this project is for SARS-CoV-2 (COVID-19) virologic assay quality assurance activities.", "keywords": [ "2019-nCoV", "Antibodies", "Biological Assay", "Biostatistical Methods", "British", "British Columbia", "COVID-19", "Clinical Trials", "Coronavirus", "Data", "Enrollment", "Ensure", "HIV", "Individual", "Laboratories", "Leukapheresis", "Multi-site clinical study", "National Institute of Allergy and Infectious Disease", "Natural History", "Neutralization Tests", "Performance", "Peripheral Blood Mononuclear Cell", "Plasma", "Plasmapheresis", "Preparation", "Quality Control", "Reagent", "Research Personnel", "Running", "SARS-CoV-2 B.1.1.7", "SARS-CoV-2 B.1.351", "SARS-CoV-2 infection", "SARS-CoV-2 variant", "Sampling", "Ships", "South Africa", "Testing", "Time", "Universities", "Variant", "pathogenic virus", "programs", "quality assurance", "repository", "variants of concern", "virology" ], "approved": true } }, { "type": "Grant", "id": "9463", "attributes": { "award_id": "75N93019C00017-P00003-9999-2", "title": "Development of a SARS-CoV-2 vaccine for the elderly by engineering virus-like particles with SARS-CoV-2 antigen and membrane-anchored cytokines", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-08-16", "end_date": "2022-08-15", "award_amount": 2199976, "principal_investigator": { "id": 25178, "first_name": "CHRISTOPHER", "last_name": "PACK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1833, "ror": "", "name": "METACLIPSE THERAPEUTICS CORPORATION", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1833, "ror": "", "name": "METACLIPSE THERAPEUTICS CORPORATION", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "Vaccine design using SARS-CoV-2 spike protein on VLPs which contain GM-CSF and IL-12 (targeting elderly). There is data supporting the premise that including GM-CSF and IL-12 in the VLP can overcome poor immune responses in elderly. Animal testing will begin using VLP with antigen and cytokines, this process will be optimized for GMP and scale-up.", "keywords": [ "2019-nCoV", "Animal Testing", "Antigens", "Data", "Development", "Elderly", "Engineering", "Granulocyte-Macrophage Colony-Stimulating Factor", "Immune response", "Interleukin-12", "Membrane", "Process", "Proteins", "Vaccine Design", "Vaccines", "Virus-like particle", "cytokine", "scale up" ], "approved": true } }, { "type": "Grant", "id": "9481", "attributes": { "award_id": "75N93019C00041-P00001-9999-2", "title": "COVID Supplement", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-30", "end_date": "2021-05-31", "award_amount": 319510, "principal_investigator": { "id": 25193, "first_name": "AARON", "last_name": "ESSER-KAHN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "The contractor had previously discovered inhibitors of the NFkB-pathway which inhibited systemic inflammation when delivered together with a TLR-agonist, while improving antibody responses induced by vaccines formulated with this combination adjuvant. They will apply this finding to subunit SARS-CoV2 vaccines and test the immunogenicity and efficacy of such novel vaccine formulations.", "keywords": [ "2019-nCoV", "Adjuvant", "Agonist", "Antibody Response", "Antibody titer measurement", "Cell Line", "Chemosensitization", "Contractor", "Ferrets", "I-kappa B Proteins", "Inflammation", "Lead", "Modeling", "Mus", "Pathway interactions", "Toxic effect", "Vaccines", "coronavirus disease", "dosage", "immunogenicity", "improved", "neutralizing antibody", "novel vaccines", "vaccine candidate", "vaccine development", "vaccine efficacy", "vaccine evaluation" ], "approved": true } }, { "type": "Grant", "id": "9495", "attributes": { "award_id": "75N93019C00044-P00002-9999-2", "title": "Adjuvant testing pipeline for recombinant SARS-CoV2 vaccines", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-30", "end_date": "2024-09-29", "award_amount": 1790282, "principal_investigator": { "id": 11930, "first_name": "OFER", "last_name": "LEVY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 798, "ror": "https://ror.org/00dvg7y05", "name": "Boston Children's Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 798, "ror": "https://ror.org/00dvg7y05", "name": "Boston Children's Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "To identify the optimal adjuvant for recombinant SARS-CoV2 vaccines for vaccine recipients of different ages, and to identify correlates of protection against SARS-CoV2 infection or disease, experimental SARS-CoV2 vaccines will be formulated with a panel of different vaccine adjuvants and tested side-by-side for immunogenicity and efficacy.", "keywords": [ "2019-nCoV", "Adjuvant", "Age", "Age-Months", "Antibodies", "Antigens", "Biological Assay", "Cells", "Contractor", "Contracts", "Disease", "Double-Stranded RNA", "Enzyme-Linked Immunosorbent Assay", "Flow Cytometry", "Government", "Immune", "Immunization", "Immunoglobulin G", "In Vitro", "Infection", "Injections", "Modeling", "Mus", "Poly I-C", "Proteins", "Reaction", "Recombinants", "Side", "Site", "Source", "Structure of germinal center of lymph node", "T-Cell Activation", "T-Lymphocyte", "Testing", "Vaccine Adjuvant", "Vaccines", "draining lymph node", "immunogenicity", "in vivo", "lymphoid organ", "novel", "polarized cell", "programs", "transcriptomics", "vaccine candidate", "vaccine evaluation" ], "approved": true } }, { "type": "Grant", "id": "9494", "attributes": { "award_id": "75N93019C00044-P00006-9999-2", "title": "Adjuvant testing pipeline for recombinant SARS-CoV2 vaccines", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-30", "end_date": "2024-09-29", "award_amount": 257000, "principal_investigator": { "id": 11930, "first_name": "OFER", "last_name": "LEVY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 798, "ror": "https://ror.org/00dvg7y05", "name": "Boston Children's Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 798, "ror": "https://ror.org/00dvg7y05", "name": "Boston Children's Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "To identify the optimal adjuvant for recombinant SARS-CoV2 vaccines for vaccine recipients of different ages, and to identify correlates of protection against SARS-CoV2 infection or disease, experimental SARS-CoV2 vaccines will be formulated with a panel of different vaccine adjuvants and tested side-by-side for immunogenicity and efficacy.", "keywords": [ "2019-nCoV", "Adjuvant", "Age", "Age-Months", "Antibodies", "Antigens", "Biological Assay", "COVID-19 vaccine", "Cells", "Contractor", "Contracts", "Disease", "Double-Stranded RNA", "Enzyme-Linked Immunosorbent Assay", "Flow Cytometry", "Government", "Immune", "Immunization", "Immunoglobulin G", "In Vitro", "Injections", "Modeling", "Mus", "Poly I-C", "Proteins", "Reaction", "Recombinants", "SARS-CoV-2 infection", "Side", "Site", "Source", "Structure of germinal center of lymph node", "T-Cell Activation", "T-Lymphocyte", "Testing", "Vaccine Adjuvant", "Vaccines", "draining lymph node", "immunogenicity", "in vivo", "lymphoid organ", "novel", "polarized cell", "programs", "transcriptomics", "vaccine candidate", "vaccine evaluation" ], "approved": true } }, { "type": "Grant", "id": "9482", "attributes": { "award_id": "75N93019C00045-P00003-9999-2", "title": "COVID - Spplement VACCINE ADJ DISCOVERY PROGRAM (VADP)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-30", "end_date": "2020-09-29", "award_amount": 3699711, "principal_investigator": { "id": 25194, "first_name": "JAY", "last_name": "EVANS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 776, "ror": "https://ror.org/0078xmk34", "name": "University of Montana", "address": "", "city": "", "state": "MT", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 776, "ror": "https://ror.org/0078xmk34", "name": "University of Montana", "address": "", "city": "", "state": "MT", "zip": "", "country": "United States", "approved": true }, "abstract": "To identify the optimal adjuvant for recombinant SARS-CoV2 vaccines, and to identify correlates of protection against SARS-CoV2 infection or disease, experimental SARS-CoV2 vaccines will be formulated with a panel of different vaccine adjuvants and tested side-by-side for immunogenicity and efficacy.", "keywords": [ "2019-nCoV", "Adjuvant", "Antibodies", "Antibody titer measurement", "Antigens", "Baculovirus Expression System", "Cells", "Cellular Immunity", "Contracts", "Development", "Disease", "Equipment", "Evaluation", "Ferrets", "Formulation", "Human", "Human Resources", "Humoral Immunities", "Infection", "Lead", "Length", "Modeling", "Mucous Membrane", "Mus", "Particle Size", "Production", "Proteins", "Recombinant Proteins", "Recombinants", "Resources", "SARS coronavirus", "Serum", "Side", "T cell response", "Testing", "Transgenic Mice", "Vaccine Adjuvant", "Vaccine Production", "Vaccines", "coronavirus disease", "cytokine", "effector T cell", "immunogenicity", "in vivo", "in vivo evaluation", "programs", "receptor", "receptor binding", "vaccine candidate", "vaccine efficacy", "vaccine evaluation", "vaccine safety" ], "approved": true } }, { "type": "Grant", "id": "9500", "attributes": { "award_id": "75N93019C00050-P00005-9999-1", "title": "CIVIC SARS-CoV-2 Research Activities", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-10", "end_date": "2022-07-31", "award_amount": 515384, "principal_investigator": { "id": 25208, "first_name": "TONY", "last_name": "MOODY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the design and evaluation of innovative candidate products and delivery platforms that aim to achieve durable, robust and broadly protective immunity against viruses.", "keywords": [ "2019-nCoV", "COVID-19 therapeutics", "Coronavirus", "Evaluation", "Immunity", "Research Activity", "Virus", "design", "innovation", "therapeutic development" ], "approved": true } }, { "type": "Grant", "id": "9499", "attributes": { "award_id": "75N93019C00050-P00005-9999-3", "title": "CIVIC SARS-CoV-2 Research Activities", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-10", "end_date": "2022-07-31", "award_amount": 1141458, "principal_investigator": { "id": 25208, "first_name": "TONY", "last_name": "MOODY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the design and evaluation of innovative candidate products and delivery platforms that aim to achieve durable, robust and broadly protective immunity against viruses.", "keywords": [ "2019-nCoV", "COVID-19", "COVID-19 vaccine", "Evaluation", "Immunity", "Research Activity", "Virus", "design", "innovation", "vaccine development" ], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1405, "count": 14046 } } }